Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) insider Shan Riku Sakakibara sold 4,000 shares of Billiontoone stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $140.21, for a total value of $560,840.00. Following the completion of the transaction, the insider owned 200,000 shares in the company, valued at $28,042,000. This trade represents a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Shan Riku Sakakibara also recently made the following trade(s):
- On Thursday, July 9th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00.
- On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00.
- On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00.
Billiontoone Price Performance
Shares of BLLN opened at $142.52 on Wednesday. The company has a 50 day moving average of $115.55 and a two-hundred day moving average of $93.87. The company has a market cap of $6.56 billion and a price-to-earnings ratio of 259.13. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $144.27.
Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analysts' expectations of $95.81 million. The business's revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.39) EPS. As a group, analysts predict that Billiontoone, Inc. will post 0.92 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
BLLN has been the subject of a number of research analyst reports. BTIG Research decreased their price target on Billiontoone from $140.00 to $130.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Guggenheim began coverage on shares of Billiontoone in a report on Monday, June 29th. They set a "buy" rating and a $125.00 price objective on the stock. Weiss Ratings upgraded shares of Billiontoone from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $126.00.
Get Our Latest Stock Analysis on BLLN
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the fourth quarter worth about $25,000. Wells Fargo & Company MN purchased a new position in Billiontoone during the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC acquired a new stake in Billiontoone during the 4th quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in shares of Billiontoone in the fourth quarter worth $201,000.
Billiontoone Company Profile
(
Get Free Report)
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
